Dr. R. Magesh is a Microbiologist with a Post Graduation in Biotechnology and a Doctorate in Computational Biology, bringing 21 years of teaching and research experience at Sri Ramachandra Institute of Higher Education and Research (SRIHER). His expertise in teaching spans Microbiology, Bioprocess Technology, Environmental Biotechnology, and Molecular Biology.
Throughout his career at SRIHER, Dr. Magesh has made significant contributions to scientific literature, with 36 high-impact international peer-reviewed research articles. His work has garnered an h-index of 11, underscoring his academic influence and the impact of his research. Additionally, he has been awarded two ICMR projects (serving as both Principal Investigator and Co-Principal Investigator), a SRIHER GATE project, and several publication awards.
Dr. Magesh’s research is focused on unraveling complex biological systems, with a commitment to leveraging these insights to develop innovative therapies and interventions aimed at enhancing human health.
PhD– “In Silico Model Driven Assessment of the effects of phenotypic variants in Amino acid metabolism disorders”
Vellore Institute of Technology -May 2014
MSc (Biotechnology)
Periyar University , May,2001
BSc (Microbiology)
Bharathidasan University, April, 1999
Principle Investigator ( 11.6lakhs ) – ICMR funded Project
In Lysosomal storage disorder the major problem is the accumulation of macromolecules in and around the organelle. Accordingly, the prevalence level was increasing and still it is been increased when the literature was reviewed. Clinical trials are in practice for possible treatments to some of these diseases and there is currently no approved treatment for many Lysosomal storage diseases (Pastores 2010). There is no much study done regarding personalized medicine and it only deals with the ERT in which it is efficient when it comes to treat patients with somatic symptoms. In case of Mucopolysaccharidosis, there is an accumulation of GAGs in various tissues and leads to damage to the heart, lungs, bones, joints, and sometimes central nervous system. In such cases, the somatic symptoms are managed, but the CNS symptoms are not because the proteins have difficulty in crossing the BBB. In most cases of the Mucopolysaccharidosis, affected people are children, and might not be compliant, and they might have further complications due to the stress involved in this procedure. . Our study sheds light on the importance of computational methods to understand the molecular nature of genetic variants and structural insights on the function of the target protein. The key outcome of this study is identify the interaction of the selected compound targeting the mutations. Mutations play a major role in the disease mechanism. To address this issue, the deleterious mutant are mapped and impact of mutation was deciphered on binding with the aid of docking analysis. Furthermore, molecular dynamics simulation was done to understand the mechanistic action of the deleterious mutation in altering the protein structure, dynamics, and stability. This study is expected to serve as a platform for drug development against Mucopolysaccharidosis and pave the way for more accurate variant assessment and classification for patients with genetic diseases in predicting the effects of functional variants on protein stability, structure, function, drug response, and protein dynamics
Co-principle Investigator ( 28 lakhs) – ICMR Funded project
UTIs are common in medical practice, with inadequate treatment posing risks of morbidity or mortality. Global concerns arise from the rising antimicrobial resistance (AMR) among uropathogens. Traditional antibiotics like co-trimoxazole and quinolones face challenges due to indiscriminate use, fostering drug-resistant bacteria. The need for rapid, decentralized testing in outpatient clinics to curb antibiotic overuse is evident. Therefore, this study employs untargeted LC-QTOF-MS/MS metabolomics and Whole Genome Metagenomic analysis. Metabolite analysis on urine samples will aid in identifying microbial metabolites in both susceptible and resistant UTI patients, whereas WGS of predominant pathogens will provide quantitative insights into UTI pathogen’s AMR gene expression in patients. This way, the research aims to identify molecular biomarkers, to differentiate patients from healthy controls so that stratification of subpopulations based on treatment options can be done to predict therapeutic responses in UTI cases.
Principle Investigator (1lakh)- GATE project Funded by Sri Ramachandra Institute of Higher Education and Research
The identification of potent compounds from Centella asiatica (commonly known as Gotu kola) for targeting Mycobacterium tuberculosis (M. tuberculosis) exhibiting monoresistance to pyrazinamide is a promising area of research, given the increasing challenge of antibiotic resistance in tuberculosis treatment. our research indicates that phytochemicals from C. asiatica may possess antimicrobial properties that could be effective against M. tuberculosis. The mechanism by which these compounds exert their effects often involves the inhibition of bacterial enzymes or disruption of cell wall synthesis. Utilizing molecular docking techniques we have identified several phytochemicals from C. asiatica with promising binding affinities to targets associated with M. tuberculosis and exhibited favorable pharmacokinetic profiles and interactions with key bacterial proteins, indicating their potential as lead candidates for further development.
These Awards received during National Science Day 2024 celebrations held at Sri Ramachandra Institute of Higher Education and Research.